Modeling the interplay between pathological angiogenesis and solid tumor growth: The anti-angiogenic treatment effect

In this paper, a previous continuum approach describing vascular tumor growth under angiogenic signaling [1] is developed and extended via the inclusion of bevacizumab pharmacokinetics. The modeling approach to the problem addressed includes inter alia the building of the model (selection of equations, related assumptions, coupling with a pharmacokinetic model tailored to the bevacizumab paradigm, implementation and numerical solution) as well as a study of the vascular tumor growth model with results for free growth and an intermittent bevacizumab mono-therapy schedule.